Publications associées à Inhibiteur de fusion

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

Philippe Colin, Aleksandar Antanasijevic

Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the persistent fraction of infectivity at maximum neutralizat ...

Public Library Science2023

Multivalent Virucidal Antivirals: Synthesis, Mechanisms of Action, and Immune-stimulating Effects

Yong Zhu

Viruses initiate invasion by binding to cell surface glycoproteins. Materials mimicking the carbohydrate motifs of these glycoproteins, such as heparan sulfate (HS) and sialic acid (SA) can block viral attachment and inhibit the infection. Multivalent disp ...

EPFL2023

Antiviral Screen against Canine Distemper Virus-Induced Membrane Fusion Activity

Gerardo Turcatti, Marc Chambon, Jonathan Patrice Vesin

Canine distemper virus (CDV), a close relative of the human pathogen measles virus (MeV), is an enveloped, negative sense RNA virus that belongs to the genus Morbillivirus and causes severe diseases in dogs and other carnivores. Although the vaccination is ...

2021

Advances in the development of entry inhibitors for sialic-acid-targeting viruses

Francesco Stellacci, Özgün Kocabiyik, Matteo Gasbarri

Over the past decades, several antiviral drugs have been developed to treat a range of infections. Yet the number of treatable viral infections is still limited, and resistance to current drug regimens is an ever-growing problem. Therefore, additional stra ...

ELSEVIER SCI LTD2021

Novel broad-spectrum virucidal antivirals

Matteo Gasbarri

The current COVID-19 pandemic has showed the threats that viruses can cause to the whole world. Over 200 million infections and over 4.5 million deaths and enormous socio-economic impact were the output of the emergence of a single new pathogen: SARS-CoV-2 ...

EPFL2021

A high-content image-based drug screen of clinical compounds against cell transmission of adenovirus

Gerardo Turcatti, Fabien Kuttler

Human adenoviruses (HAdVs) are fatal to immuno-suppressed individuals, but no effective anti-HAdV therapy is available. Here, we present a novel image-based high-throughput screening (HTS) platform, which scores the full viral replication cycle from virus ...

2020

HIV peptidome-wide association study reveals patient-specific epitope repertoires associated with HIV control

Jacques Fellay, Nimisha Chaturvedi, Paul Jack Mc Laren

Genetic variation in the peptide-binding groove of the highly polymorphic HLA class I molecules has repeatedly been associated with HIV-1 control and progression to AIDS, accounting for up to 12% of the variation in HIV-1 set point viral load (spVL). This ...

National Academy of Sciences2019

Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity

Harm-Anton Klok, Maarten Danial, Frederik Roman Wurm

A popular strategy for overcoming the limited plasma half-life of peptide heptad repeat 2 (HR2) fusion inhibitors against HIV-1 is conjugation with biocompatible polymers such as poly(ethylene glycol) (PEG). However, despite improved resistance to proteoly ...

2017

Polyvalent Side Chain Peptide-Synthetic Polymer Conjugates as HIV-1 Entry Inhibitors

Harm-Anton Klok, Maarten Danial

This report describes the synthesis and properties of a series of polyvalent side chain peptide synthetic polymer conjugates designed to block the CD4 binding site on gp120 and inhibit HIV-1 entry into a host cell. The peptide sequences in the conjugates a ...

American Chemical Society2012

Combating HIV Type 1 with Peptide - Synthetic Polymer Conjugates

Maarten Danial

Polymer therapeutics is a class of (bio)hybrid materials that include a plethora of biologically active (synthetic) macromolecules that either consist of polymeric drugs, drug-polymer conjugates, peptide/protein-polymer conjugates or of drug, peptide or pr ...

EPFL2011